On October 14, Dr. David Cahn successfully performed one of the first procedures with INLEXZO™ (gemcitabine intravesical system), following its U.S. FDA approval in September.
For patients battling bladder cancer who haven’t responded to standard therapy, the next step has often been radical, life-altering bladder removal surgery. But new procedures like INLEXZO, which delivers cancer medication directly into the bladder, and other new powerful drugs are providing much-needed alternatives for those who don’t want or can’t undergo major surgery.
In a recent interview with Urology Times, Dr. Cahn discusses his experience performing one of the first procedures using this new technology, as well as the evolving treatment landscape for patients with non-muscle-invasive bladder cancer.
He also discusses some of the factors that urologists and their patients must consider when evaluating the risks and benefits of each option.
Read the complete interview at Urology Times.
